Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01261247 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41
Last updated 2022-05-24
Summary
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma
Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Hepatosplenic T-cell Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Peripheral T-cell Lymphoma
- Post-transplant Lymphoproliferative Disorder
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- DRUG
-
panobinostat
Given orally
- OTHER
-
laboratory biomarker analysis
Correlative studies
- GENETIC
-
western blotting
Correlative studies
- GENETIC
-
DNA analysis
Correlative studies
- OTHER
-
flow cytometry
Correlative studies
- OTHER
-
pharmacological study
Correlative studies
- OTHER
-
immunohistochemistry staining method
Optional correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Patrick Johnston, M.D. · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-17
- Primary Completion
- 2016-05-09
- Completion
- 2019-12-02
Countries
- United States
Study Locations
More Related Trials
-
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT01460940 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
NCT01028313 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
NCT00901147 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
NCT01321346 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Panobinostat in Patients With Neuroendocrine Tumors
NCT00985946 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
NCT00490776 ·Status: TERMINATED ·Phase: PHASE2
-
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00058019 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
NCT05272384 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT05563844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
NCT03484819 ·Status: COMPLETED ·Phase: PHASE2
-
Panobinostat Biological Correlates Study
NCT01658241 ·Status: COMPLETED ·Phase: PHASE2
-
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
NCT00936611 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
NCT00089089 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
NCT01034163 ·Status: COMPLETED ·Phase: PHASE3
-
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
NCT02961816 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
NCT01090973 ·Status: TERMINATED ·Phase: PHASE2
-
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
NCT00743288 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Neoplasms or Lymphomas
NCT03316573 ·Status: SUSPENDED ·Phase: PHASE2
-
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02168907 ·Status: TERMINATED ·Phase: PHASE1
-
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075553 ·Status: TERMINATED ·Phase: PHASE2
-
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03526250 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
NCT05627245 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1